Revvity (RVTY)

Health Care · $17.8B market cap · SEC CIK 0000031791

Next reports on Feb 1, 2027, after the close, with analysts expecting $1.65 in earnings per share.

52-week range $81.22 to $171.74. 7% below its 52-week high and 96% above its low.

The case for RVTY

• Generated $509M of free cash flow in FY2025, 18% of revenue.
• Gross margin of 56% absorbs cost shocks.
• Current assets cover the near-term bills 2.7 times over.
• Up 77.0% over the past year.

The case against

• Expensive for its growth: 70.3× earnings, where 0% a year of growth would justify about 8×.
• Revenue has shrunk 5.5% a year over five years.
• Priced at 6.1× sales with revenue growing only 4.6%.
• Return on equity of only 4%.
• Stability is weak (32/100): beta 1.06, 4.5 years of cash flow to clear its debt, a 53% swing over the year.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from Revvity's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Revvity says it does

Overview We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Our headquarters are in Waltham, Massachusetts, and we market our products and services in more than 160 countries. As of December 28, 2025, we employed approximately 11,000 employees. Our common stock is listed on the New York Stock Exchange under the symbol “RVTY” and we are a component of the S&P 500 Index. We maintain a website with the address http://www.revvity.com . We are not including the information contained in our website as part of, or incorporating it by reference into, this annual report on Form 10-K. We…

Risk factors RVTY lists in its 10-K

• Our growth and profitability are subject to global economic and political conditions, and operational disruptions at our facilities
• If we do not introduce new products in a timely manner, we may lose market share and be unable to achieve revenue growth targets
• If we do not compete effectively, our business will be harmed
• If we do not retain our key personnel, our ability to execute our business strategy will be limited
• Uncertainties related to the development, deployment and use of AI to advance our product offerings and improve internal operations may result in harm to our business and reputation
• We may not be successful in adequately protecting our intellectual property
• If we are unable to renew our licenses or otherwise lose our licensed rights, we may have to stop selling products or we may lose competitive advantage
• The manufacture and sale of products and services may expose us to product and other liability claims for which we could have substantial liability
• Changes in governmental regulations may reduce demand for our products or increase our expenses
• Economic, political and other risks associated with foreign operations could adversely affect our international sales and profitability
• We have a substantial amount of outstanding debt, which could impact our ability to obtain future financing and limit our ability to make other expenditures in the conduct of our business
• Restrictions in our senior unsecured revolving credit facility and other debt instruments may limit our activities
• Dividends on our common stock could be reduced or eliminated in the future

Filings

Other Health Care companies